Anksiyöz depresyon: Bir depresyon alt grubu mu?

Araştırmalar anksiyetenin klinik depresyonda en belirgin belirti olduğunu ve depresyonun başarılı sağaltımı için şiddetli ve dirençli anksiyetenin önemli olduğunu önermektedir. Anksiyöz depresyon terimi düşünülürken, hastaların anksiyete ve depresyon belirtilerini üç şekilde gösterebileceği göz önünde tutulmalıdır: Komorbid anksiyete ve depresyon, depresyon ve eşik altı anksiyete, eşik altı depresyon ve eşik altı anksiyete. Depresyon ve anksiyete arasındaki ilişkinin henüz net olmamasına rağmen anksiyöz depresyon teriminin eşik altı anksiyete belirtileri gösteren depresyon için kullanılması gerektiği belirtilmektedir. Depresyon hastalarında anksiyete, şiddet, düşük tedavi yanıtı ve özkıyımın belirtecidir. Yüksek anksiyeteye sahip depresyon hastalarında hastalık daha şiddetli, iyileşme daha uzun, antidepresanlara yanıt daha düşüktür. Bu yazıda bu grup hastalarda en uygun tedavi gözden geçirilmiştir. Bu konuda prevalans, klinik özellikler ve tedaviyi daha iyi anlamak için daha fazla çalışmaya gereksinim vardır.

Anahtar Kelimeler:

Kaygı, Depresyon

Anxious depression: is it a subgroup of depression?

The current evidence suggests that anxiety is one of the most prevalent symptoms in clinical depression and that assessment and treatment of severe, persistent anxiety is of great importance in successful treatment of depression. When considering anxious depression term, it should be recognized that patients can manifest symptoms of depression and symptoms of anxiety in 3 separate ways; as comorbid depression and anxiety, as depression with subthreshold anxiety, and as subthreshold depression with subthreshold anxiety. The nature of the link between depression and anxiety remains uncertain, however, based on the evidence to date, the term anxious depression be reserved for patients who meet diagnostic criteria for depression and have subthreshold symptoms of an anxiety disorder. In depressed patients, anxiety is a marker of severity, poor outcome, poor response to treatment, and suicide risk. Depressed patients who have higher ratings for anxiety are more severely ill, take longer to recover, and show poor response to antidepressants. In this paper we aimed to review the most appropriate treatment for this group of patients. It is also evident that more research needs to be undertaken in this important patient group in order to understand its prevalence, clinical features, and treatment.

Keywords:

Anxiety, Depression,

PDF

___

1. Lydiard RB, Brawman-Mintzer O. Anxious depression. J Clin Psychiatry 1998; 59(suppl.18):10-17.
2. BoulengerJP, Lavallee YJ. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993;54(Suppl.1):3-8.
3. Küey L, Aydemir Ö. Majör depresyon, anksiyete bozukluğu ve eştanılı durumlarda ayrışan ve örtüşen özellikler-1 . Turk Psikiyatri Derg 1996; 7:257-265.
4. Fava GA, Kellner R. Prodromal symptoms in affective disorders. Am J Psychiatry 1991; 148:823-830.
5. Cloninger CR. Comorbidity of anxiety and depression. J Clin Psychopharmacol 1990; 10:43S-46S.
6. Nutt D. Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry 1997:58(Suppl.8):11-16.
7. Clayton PJ. The comorbidity factor establishing the primary diagnosis in. patients with mixed symtoms of anxiety and depression. J Clin Psychiatry 1990; 51(suppl.11):35-39.
8. Fawcett J. The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 1997; •58(Suppl.8):35-40.
9. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry 1993; 54(Suppl.2):10-14.
10. Clayton PJ,. Grove WM. Follow-up and family study of anxious depression. Am J Psychiatry 1991; 148:1512- 1517.
11. Kaya B, Ünal S. Karma anksiyete ve depresyon bozukluğu. Psikiyatri Dünyası 2001; 5:80-88.
12. Hiller W, Zauding M, Bose M. The overlap between depression and anxiety on different levels of psychopathology. J Affect Disord 1989; 16:223-23.
13. Silverstone PH, Studnitz E. Defining anxious depression: going beyond comorbidity. Can J Psychiatry 2003;48:675-680.
14. Ninan PT, Rush AJ. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 2002; 63:434-441.
15. Clark DA, Beck AT, Beck JS. Symptom differences in major depression, dysthymia, panic disorder, and generalized anxiety disorder. Am J Psychiatry 1994;151:205-209.
16. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol 1991; 103:316-336.
17. Sevinçok L. Yaygın anksiyete bozukluğunda tanı ve eştanı sorunları. Duygudurum Dizisi 2001; 3:144-151.
18. Boulenger JP, Foumier M. Mixed anxiety and depression: from theory to practice. J Clin Psychiatry 1997;58(suppl.8):27-34.
19. Zinbarg RE, Barlow DH, Liebowitz M, Street L, Broadhead E, Katon W ve ark. The D.SM-IV field trial for mixed anxiety-depression. Am J Psychiatry 1994; 151:1153-1162.
20. Fidaner H, Alkin T. Mik;st anksiyete depresyon ve eştanılı durumlar. Duygudurum Dizisi 2001; 4:169-176.
21. Schatzberg AF, Samson JA, Rothschild AJ, Luciana MM, Bruno RF, Bond TC. Depression secondary to anxiety: findings from the McLean Hospital Research Facilities. Psychiatr Clin North Am 1990; 13:633-649.
22. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996; 168(Suppl.30):17-30.
23. Judd LL, Kessler RC, Paulus MP, Zeller PV, Wittchen HU, Kunovac JL. Comorbidity was a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study. Acta Psychiatr Scand 1998; (Suppl.393):6-11.
24. Zajecka JM. The effects of nefazodone on .comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatientssettings. J Clin Psychiatry 1996; 57(Suppl.2):10-14.
25. Taneli B, Taneli Y, Taneli T. Depresyon ve anksiyete bozukluklarının birlikte bulunmaları ve psikofarmakolojik tedavi yaklaşımı. Psikiyatri Dünyası 2001; 5:115-129.
26. Gibbons RD, Clark CD, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure. J Psychiat Res 1993; 27:259-273.
27. Boratav C, Koç A. Anksiyetenin eşlik ettiği depresyon olgularının hepsinde depresif bozukluk olmayabilir: Karşılaştırmalı bir izlem çalışması. Klinik Psikiyatri Dergisi 2003; 6:18-26.
28. Joffe RT, Bagby RM. Anxious and nonanxious depression. Am J Psychiatry 1993; 150:1257-1258.
29. Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. J Clin Psychiatry 1995; 3:2-12.
30. Fava M, Rosenbaum JF. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000;59:119-126.
31. Joliat MJ, Schmidt ME, Fava M. Long-term treatment: outcomes of depression with associated anxiety, efficacy of continuation treatment with fluoxetine. J Clin Psychiatry 2004; 65:373-378.
32. Fava M, Rosenbaum JF, Hoog S, Tepner R, KoppJ. Fluoxetine versus sertraline and paroxetine in major depression: safety and efficacy in anxious and nonanxious subgroups. Biol Psychiatry 1998; 43:1S-133S.
33. Flicker C, Hakkarainen H. Citalopram in anxious depression: anxiolytic effects and lack of activation. Biol Psychiatry 1998; 43:1S-133S.
34. Fawcett J, Barkin RL. A meta-analysis of 8 randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of patients with major depression. J Affect Disord 1998; 51:267-285.
35. Silverstone PH, Ravindran A. Efficacy and tolerability of once daily venlafaxine XR vs fluoxetine in depressed outpatients with concomitant anxiety. J Clin Psychiatry 1999; 60:22-28.
36. Tollefson GD, Holman SL. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry Monograph 1995; 13:13-22.